A novel case of endometrial dedifferentiated adenocarcinoma associated with MLH1 promotor hypermethylation and microsatellite instability.

Pathol Res Pract

Department of Pathology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing, 100191, PR China; Department of Pathology, Peking University Third Hospital, Beijing, 100191, PR China. Electronic address:

Published: November 2018

Endometrial dedifferentiated carcinoma is a rare, malignant tumor whose molecular alterations have not been clarified yet. We report a novel case of a 61-year old woman who presented with irregular vaginal bleeding after menopause and a 3 cm uterus mass. Histology revealed endometrial dedifferentiated adenocarcinoma, a rare subtype comprised of undifferentiated adenocarcinoma. The patient still survived 1 year after surgery without chemotherapy and radiotherapy. Immunohistochemistry revealed loss of MLH1/PMS2 expression and retained MSH2/MSH6 expression. Consistently, microsatellite instability was detected indicative of high microsatellite instability (MSI-H). No BRAF V600E, KRAS and POLE mutations were identified. Remarkably, the promoter regions of mutL homolog 1(MLH1) were methylated. Furthermore, several tumor cells were PD-L1 positive in this case with a concentration at the infiltrating tumor edge indicating MSI-H in endometrial dedifferentiated adenocarcinoma is a potential predictive factor for response to immunotherapy targeting the PD-1 or its ligand PD-L1.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2018.08.015DOI Listing

Publication Analysis

Top Keywords

endometrial dedifferentiated
16
dedifferentiated adenocarcinoma
12
microsatellite instability
12
novel case
8
endometrial
4
case endometrial
4
dedifferentiated
4
adenocarcinoma
4
adenocarcinoma associated
4
associated mlh1
4

Similar Publications

Anaemia, blood transfusions and survival in high-grade endometrial cancer: retrospective study.

BMJ Support Palliat Care

December 2024

Department of Obstetrics, Gynecology and Reproductive Sciences, University of Manitoba, Winnipeg, Manitoba, Canada.

Objective: To determine if anaemia and blood transfusions in the perioperative, chemotherapy and radiation treatment periods are associated with overall survival (OS) and recurrence-free survival (RFS) in high-grade endometrial cancer.

Methods: This retrospective cohort study examined patients at a single centre treated for high-grade endometrial cancer (2010-2023). This included International Federation of Gynecology and Obstetrics (FIGO) grade 3 endometrioid, serous, carcinosarcoma, mixed, clear cell, mucinous, dedifferentiated and undifferentiated histology.

View Article and Find Full Text PDF

Undifferentiated endometrial carcinoma diagnosed during perimenopausal hormone therapy: a case report and literature review.

Front Oncol

November 2024

The Taizhou Central Hospital (Taizhou University Hospital), School of Medicine, Taizhou University, Taizhou, Zhejiang, China.

Uterine corpus endometrial carcinoma, one of the three most frequent cancers of the female reproductive system, primarily affects women who are perimenopausal or postmenopausal. Moreover, it is an epithelial cancer that develops in the endometrium, which is classified as either estrogen-dependent (type I) or non-estrogen-dependent (type II). Non-estrogen-dependent endometrial cancers include plasma cell carcinoma and undifferentiated/dedifferentiated endometrial carcinoma.

View Article and Find Full Text PDF
Article Synopsis
  • Endometrial cancer is a significant health issue for women worldwide, being the sixth most common cancer and the 14th leading cause of cancer-related deaths, particularly for high-grade tumors like UEC, DEC, and CS.
  • The study analyzed data from 71 patients diagnosed with these aggressive tumors at SKMCH&RC from 2011 to 2022, focusing on clinicopathological characteristics and survival rates using statistical tools like SPSS and Kaplan-Meier analysis.
  • Results indicated that tumors showed significant correlations with factors such as myometrial invasion and lympho-vascular invasion, with a notable 5-year overall survival rate of 59.1% for those diagnosed at an early pathological stage.
View Article and Find Full Text PDF

[Dedifferentiated endometrial carcinoma/undifferentiated endometrial carcinoma with loss of expression of SMARCA4: clinicopathological features analysis].

Zhonghua Fu Chan Ke Za Zhi

November 2024

Department of Pathology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou350014, China.

To investigate the clinicopathological characteristics of dedifferentiated endometrial carcinoma/undifferentiated endometrial carcinoma (DDEC/UDEC) with loss of expression of SMARCA4. A total of 10 cases with loss of expression of SMARCA4 were diagnosed at Fujian Cancer Hospital between January 2019 and December 2023. A retrospective analysis was conducted on the clinical characteristics, morphology, immunophenotype, molecular classification, and prognosis.

View Article and Find Full Text PDF

About 20% of human cancers harbor mutations of genes encoding switch/sucrose nonfermentable (SWI/SNF) complex subunits. Deficiency of subunits of the complex is present in 10% of non-small-cell lung cancers (NSCLC; SMARCA4/SMARCA2 deficient), 100% thoracic SMARCA4/A2-deficient undifferentiated tumors (TSADUDT; SMARCA4/A2 deficient), malignant rhabdoid tumor, and atypical/teratoid tumor (SMARCB1-deficient), >90% of small cell carcinoma of the ovary, hypercalcemic type (SMARCA4/SMARCA2 deficient), frequently in undifferentiated/dedifferentiated endometrial carcinoma (SMARCA4, SMARCA2, SMARCB1, and ARID1A/B deficient), 100% SMARCA4 deficient undifferentiated uterine sarcoma (SMARCA4 deficient); and in various other tumors from multifarious anatomical sites. Silencing of SWI/SNF gene expression may be genomically or epigenetically driven, causing loss of tumor suppression function or facilitating other oncogenic events.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!